Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

GVAX prostate cancer vaccine enters additional phase I/II trial

April 9, 1999

NeoPharm to collaborate with NCI on cytotoxic cancer ligand

April 9, 1999

Progress with AltaRex's AIT products for cancer

April 8, 1999

M-Vax cancer vaccine granted orphan drug designation

April 6, 1999

Antisoma's Theragyn granted orphan drug status in the U.S.

April 6, 1999

DSMB completes interim evaluation of Maxamine phase III clinical trials

April 1, 1999

Reanalysis of data attributes greater efficacy to Multikine

March 30, 1999

Procyon receives Canadian patent for PSP94

March 30, 1999

AltaRex updates OvaRex MAb and BrevaRex MAb clinical progress

March 29, 1999

Maxim allowed additional U.S. patent for Maxamine technology

March 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...